Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in Severe Keratitis
NCT04169061Phase 4Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repository corticotropin injection in Noninfectious Keratitis, sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Impact of Dry Eye on Everyday Life (IDEEL) Scale - Symptom Bother Module at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
Noninfectious Keratitis
Beyond the preview
Go deeper on NCT04169061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169061.